Summary
Erythromycins often cause gastrointestinal side-effects due to an increase in motility or to change in the intestinal bacterial flora. In order to evaluate the effect of erythromycin on gastrointestinal motility, 11 healthy volunteers were given placebo, erythromycin stearate (ES) 1000 mg or a therapeutically equivalent single dose of erythromycin acistrate (EA, 2′-acetyl erythromycin stearate) 800 mg in a double-blind trial. The orocaecal transit time was measured using the hydrogen breath test with lactulose as the substrate. The transit time was estimated from the H2-peak (ppm) in end-expiratory breath by two methods, t1 representing the “front” and t2 the “bulk” of lactulose reaching the colon.
t1 was 51 min in the placebo group, 38 min in the EA and 31 min in the ES group (p < 0.05, ES vs placebo). t2 was 74 min, 64 min, and 46 min, respectively (p < 0.05, ES vs placebo). The difference between EA and ES was also significant. Six subjects in the ES group but none in the EA group recorded adverse gastrointestinal effects attributable to medication.
It was concluded that erythromycin shortens the orocaecal transit time in man and that EA affects the transit time slightly less than ES.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anonymous (1985) Oral erythromycin. Med Let Drugs Ther 27: 1–3
Weinstein AJ, Alanis A (1984) Antibiotic side effects. In: Ristuccia AM, Cunha BA (eds) Antimicrobial Therapy, Raven Press, New York, pp 339–363
Carter BL, Woodhead JC, Cole KJ, Milavezt G (1987) Gastrointestinal side effects with erythromycin preparations. Drug Intell Clin Pharm 21: 734–738
Eichenwald HF (1986) Adverse reactions to erythromycin. Pediatr Infect Dis 5: 147–150
Heimdahl A, Kager L, Nord CE (1985) Changes in the oropharyngeal and colon microflora in relation to antimicrobial concentrations in saliva and faeces. Scand J Infect Dis [Suppl] 44: 52–58
Heimdahl A, Nord CE (1982) Effect of erythromycin and clinidamycin on the indigenous anaerobic flora and new colonization of the gastrointestinal tract. Eur J Clin Microbiol 1: 38–48
Zara GP, Thompson HH, Pilot MA, Ritchie HD (1985) Effects of erythromycin on gastrointestinal tract motility. J Antimicrob Chemother 16 [Suppl A]: 175–179
Itoh Z, Suzuki T, Nakaya M, Inoue M, Mitsuhashi S (1984) Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrob Agents Chemother 26: 863–869
Itoh Z, Suzuki T, Nakaya M, Inoue M, Arai H, Wakabayashi K (1985) Structure-activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract. Am J Physiol 248: G320-G325
Gordin A, Männistö PT, Antikainen R, Ylikoski J, Savolainen S (1988) Concentrations of erythromycin, 2-acetyl erythromycin and their anhydro forms in plasma and tonsil tissue after repeated dosage of erythromycin stearate and erythromycin acistrate. Antimicrob Agents Chemother 32: 1019–1024
Männistö PT, Taskinen J, Ottoila P, Vuorela A, Nykänen S (1988) Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analyzed by mass-spectrometry in plasma of healthy human volunteers. J Antimicrob Chemother [Suppl D] 21: 33–43
Savolainen S, Männistö PT, Gordin A, Antikainen R, Tuominen RK, Haataja H, Ylikoski J (1988) Tonsillar penetration of erythromycin and its 2′-acetyl ester in patients with chronic tonsillitis. J Antimicrob Chemother [Suppl D] 21: 73–84
Gordin A, Kalima S, Hulmi S, Mäkelä P, Antikainen R (1988) Comparison of erythromycin acistrate and enterocoated erythromycin base in acute respiratory infections. J Antimicrob Chemother [Suppl D] 21: 85–92
Gordin A, Salmi HA, Antikainen R (1988) Erythromycin acistrate and enterocoated pellets of erythromycin base in acute respiratory infections of hospitalized conscripts. J Antimicrob Chemother [Suppl D] 21: 93–100
Wuolijoki E, Flygare U, Hildén M, Hurme J, Järvinen H, Leskinen J, Pynnönen S, Riikonen A, Salomaa V, Seuri M, Sysiö K, Teirilä J, Antikainen R, Gordin A (1988) Treatment of respiratory tract infections with erythromycin acistrate and two formulations of erythromycin base. J Antimicrob Chemother [Suppl D] 21: 107–112
Bond JH, Kevitt MD (1975) Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements. J Lab Clin Med 85: 546–555
Corbett CL, Thomas S, Read NW, Hobson N, Bergman I, Holdsworth CD (1981) Electrochemical detector for breath hydrogen determination: Measurement of small bowel transit time in normal subjects and patients with the irritable bowel syndrome. Gut 22: 836–840
Diggory RT, Cushieri A (1985) The effect of dose and osmolality of lactulose on the oro-caecal transit time determined by hydrogen breath test and the reproducibility of the test in normal subjects. Ann Clin Res 17: 331–333
Tobin MV, Fisken RA, Diggory RT, Morris AI, Gilmore IT (1989) Orocaecal transit time in health and thyroid disease. Gut 30: 26–29
Staniforth DH, Rose D (1989) Statistical analysis of the lactulose/breath hydrogen test in the measurement of orocaecal transit time: its variability and predictive value in assessing drug action. Gut 30: 171–175
Vijaykumar P, Patel MD, Naresh K, Jain MD, Capecomorin S, Pitchumoni MD (1986) Factors affecting fasting breath hydrogen levels in healthy adults: A study in two continents. Am J Gastroentorol 81: 771–773
Gilant T, Ben Hur H, Gelman-Malachi E, Terdiman R, Peled Y (1978) Alterations of colonic flora and their effect on hydrogen breath test. Gut 19: 602–605
Basilisco G, Bozzani A, Cambolni G, Recchia M, Quatrini M, Conte D, Penagini R, Bianci PA (1985) Effect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath test. Gut 26: 700–703
O'Brien JD, Thompson DG, McIntyre A, Burnham WR, Walker E (1988) Effect of codein and loperamide on upper intestinal transit and absorption in normal subjects and patients with postvagotomy diarrhoea. Gut 29: 312–318
Staniforth DH (1987) Effect of drugs on oro-caecal transit time assessed by lactulose/breath hydrogen method. Eur J Clin Pharmacol 33: 55–58
Van Rooy F, Creve U, Verlinden M, Hubens A (1988) Effect of cisapride on the post-cholecystectomy upper gastrointestinal transit time. Int J Clin Pharmacol Ther Toxicol 26: 265–268
Van Wyk M, Sommers De K, Steyn AGW (1985) Evaluation of gastrointestinal motility using hydrogen breath test. Br J Clin Pharmacol 20: 479–481
Caride VJ, Prokop EK, Troncale FJ, Buddoura W, Winchenbach K, McCallum RW (1984) Scintigraphic determination of small intestinal transit time: Comparison with the hydrogen breath technique. Gastroenterology 86: 714–720
Hirakawa M, Iida M, Kohrogi N, Fujishima M (1988) Hydrogen breath test assessment of orocecal transit time: Comparison with barium meal study. Am J Gastroenterol 83: 1361–1363
Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K (1984) Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Gastrointest Liver Physiol 247: 688–694
Pilot MA, Qin XY (1988) Macrolides and gastrointestinal motility. J Antimicrob Chemother [Suppl B] 22: 201–206
Tomomasa T, Kuroume T, Arai H, Wakabayashi K, Itoh Z (1986) Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci 31: 157–161
Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, Bouillon R (1990) Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 322: 1028–1031
Kaukoranta-Tolvanen SS, Renkonen OV, Gordin A, Tamm L, Männistö P (1989) Effect of erythromycin acistrate and erythromycin stearate on human colonic microflora. Scand J Infect Dis 21: 717–720
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lehtola, J., Jauhonen, P., Kesäniemi, A. et al. Effect of erythromycin on the oro-caecal transit time in man. Eur J Clin Pharmacol 39, 555–558 (1990). https://doi.org/10.1007/BF00316094
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00316094